MedTrace Logo

A Study of Sacituzumab Govitecan in People With Mesothelioma

NCT06477419 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-05-05

No results posted yet for this study

Summary

Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

Conditions

Interventions

DRUG

Sacituzumab govitecan-hziy

After enrollment, participants will receive SG until disease progression or intolerable toxicity.

Sponsors & Collaborators

Principal Investigators

  • Michael Offin, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2029-06-21
Completion
2029-06-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477419 on ClinicalTrials.gov